Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: We commend Dr Hulley and
colleagues1 on a well-designed, first-ever randomized trial
to evaluate continuous estrogen-progestin hormone replacement therapy
(HRT) for the secondary prevention of coronary heart disease (CHD).
Surprisingly and disturbingly, the results do not support the
beneficial effects of HRT found in observational studies.
Pan CX, Boal J, . Hormone Replacement Therapy for Secondary Prevention of Coronary Heart Disease. JAMA. 1999;281(9):794–797. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-9-jbk0303
Customize your JAMA Network experience by selecting one or more topics from the list below.